01 sep 25   hvivo plc - appointment of non-executive chair hvivo plc | hvo | 9.9 0 0.0% | mkt cap: 68.0m    rns number : 3425x hvivo plc 01 september 2025   hvivo plc ("hvivo", the "company" or the "group")   appointment of non-executive chair   hvivo plc (aim: hvo), a full-service contract research organisation (cro) and the world leader in human challenge clinical trials, confirms that, further to its announcement on 29 july 2025, shaun chilton has today joined the board of directors as non-executive chair with immediate effect.   shaun brings substantial sector-relevant experience and expertise to the board, underpinned by a track record of delivering strong growth in sales and enterprise value. he brings over 30 years of experience leading and managing both private and public businesses. shaun was previously chief executive officer of clinigen group plc, a global pharmaceutical services group operating in more than 100 countries and has considerable board experience within uk public companies. he is currently non-executive chair of avacta group plc, non-executive chair of kintiga limited, and independent supervisory board member of product life group.   elaine sullivan, interim chair & senior non-executive director of hvivo plc, said: "we are delighted to welcome shaun to the board of hvivo. shaun brings a wealth of sector-relevant experience and we believe his expertise will support us as we continue to grow and diversify the group. as a board we look forward to working closely with shaun to help deliver on the company's mission and execute on our strategy."   shaun chilton, incoming non-executive chair of hvivo plc, said: "i am pleased to join the board of hvivo plc, a company which i believe has excellent prospects as it continues to diversify its service offering while leading the global charge in delivering exceptional human challenge trial services to its clients."   additional information on the board appointment   the following additional information is provided with regards to the appointment of shaun edward chilton, aged 57, in accordance with rule 17 and schedule 2(g) of the aim rules for companies:   current directorships/partnerships: former directorships/partnerships (within the last five years): avacta group plc c7 health limited bellbrook consulting limited clinigen clinical trials limited mustang bidco limited clinigen consulting limited mustang midco limited clinigen cts limited mustang topco limited clinigen gap limited  clinigen healthcare limited  clinigen holdings limited  clinigen international holdings limited  clinigen limited  clinigen pharma limited  definigen limited  idis ga limited  idis group holdings limited  idis group limited idis limited  idis ma limited  idis pharma limited  iovance biotherapeutics uk sp ltd  keats healthcare limited   shaun does not hold any shares or options in the company.   there are no further disclosures required under rule 17 and schedule 2(g) of the aim rules for companies.   for further information please contact:   hvivo plc +44 (0)20 7756 1300 yamin 'mo' khan, chief executive officer stephen pinkerton, chief financial officer    cavendish capital markets limited (nominated adviser and joint broker) +44 (0)20 7220 0500 geoff nash, callum davidson trisyia jamaludin, harriet ward nigel birks - life science specialist sales louise talbot - sales    peel hunt llp (joint broker) +44 (0)20 7418 8900 james steel, dr christopher golden    davy (joint broker) +353 (0) 1 679 6363 anthony farrell, niall gilchrist    walbrook pr (financial pr & ir) paul mcmanus / alice woodings  lianne applegarth +44 (0)20 7933 8780 or hvivo@walbrookpr.com +44 (0)7980 541 893 / +44 (0)7407 804 654 +44 (0)7584 391 303       notes to editors   hvivo plc (ticker: hvo) is full-service contract research organisation (cro) and the global leader in human challenge trials. the company delivers end-to-end clinical development services to a diverse and expanding client base, including seven of the world's ten largest biopharma companies.   hvivo specialises in conducting human challenge trials across multiple infectious and respiratory indications, leveraging its state-of-the-art quarantine facility in london-the largest of its kind worldwide. the company also offers comprehensive virology and immunology laboratory services under the hlab brand.   through its german subsidiary, crs, hvivo operates a 120-bed capacity across mannheim and kiel, providing early-phase clinical trial services, including first-in-human and proof-of-concept studies. its second subsidiary, venn life sciences, offers early drug development consulting and biometry services to the biopharma sector.   the group provides fully integrated drug development solutions from preclinical stages through phase ii trials, alongside patient recruitment via flucamp. additionally, its five clinical sites support outpatient phase ii and iii trials, ensuring a seamless and efficient pathway from discovery to late-stage development.   this information is provided by rns, the news service of the london stock exchange. rns is approved by the financial conduct authority to act as a primary information provider in the united kingdom. terms and conditions relating to the use and distribution of this information may apply. for further information, please contact rns@lseg.com or visit www.rns.com.  rns may use your ip address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. for further information about how rns and the london stock exchange use the personal data you provide us, please see our privacy policy.   end   boasdlfwfeisesa return to news summary

Label: Gesunken